Metrologic Instruments, Inc.

Risen (suzhou) Pharma Tech Co., Ltd.

Hand Held Products, Inc.

Legend Biotech USA Inc.

Jiangsu Hengrui Medicine Company Ltd.

Nanjing University of Posts and Telecommunicatins

Changshu Institute of Technology

Tenneco (suzhou) Emission System Co., Ltd.

Brigates Microelectronics (kunshan) Co., Ltd

Getein Biotech, Inc.

Lin Wang

Xiaoxun Zhu

C Harry Knowles

Ka Man Au

Mark C Schmidt

Patrick Anthony Giordano

George B Rockstein

Stephen J Colavito

Garrett K Russell

Robert E Blake

Sung Byun

John Bonanno

Donald T Hudrick

Congwei Xu

Min Jiang

Hongjian Jin

Meng Hu

MingQing Ji

Shamei Shi

David M Wilz

Xianqi Kong

Jiasheng Lu

Jiamin Gu

Xiang Ji

Dongdong Wu

Xiuchun Zhang

Daiqiang Hu

Qiuchuan Zhuang

Pingyan Wang

Lei Yang

Xiaohu Fan

Xinyong Lv

Dongqing Zhu

Xiaolin He

Jiaying Hao

Jun Yin

Yunxin Ouyang

Jianfeng Gao

Zhongqi Liu

Gang Chen

Likun Wang

Jian Li

Jinchao Ai

Feng Zhou

Zhengyang Xie

Hongfeng Huang

Yunsheng Pi

Chen Feng

Jie Ren

Chuan-Chu Chou

Li Wang

Hui Li

Yuefeng Mo

Qiyun Shao

Cong Wang

Zhenxing Du

Ping Wang

Jing Li

Dan Zhao

Xian He

Lingzhi Yin

Lei Zhu

Wenzhe Luo

Bo Li

Qiguo Zhang

Liangwei Lv

Xuli Wang

Junran Yang

Jinchao Al

Qiaoping Yue

Changping Liang

Enben Su

Feng Yi

Weisen Chen

Junjun Liu

Jing Jin

Chengyong Sun

David M Witz, Sr

Yumei Chang

Yaming Bo

Mark S Schmidt

Ming Qing Ji

Ming Jiang

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a manual of joint and bone disorders such as arthritis and osteoporosis.

Glucosamine derivatives for the prevention or treatment of joint disorders

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.

A sealing device for a gas-liquid two-phase fluid medium under variable working conditions includes a rotating shaft and a housing, and a chamber formed by the housing is configured to accommodate the gas-liquid two-phase fluid medium. The sealing device further includes a labyrinth sealing mechanism and a fluid dynamic-pressure mechanical sealing mechanism with double end faces, where the labyrinth sealing mechanism and the fluid dynamic-pressure mechanical sealing mechanism with double end faces conduct mutual synergetic effect. Sealing buffer chambers are arranged between the labyrinth sealing mechanism and the fluid dynamic-pressure mechanical sealing mechanism; the fluid dynamic-pressure mechanical sealing mechanism is provided with stationary rings and movable rings, where the stationary rings and the movable rings oppositely abut against with each other.

Sealing device for gas-liquid two-phase fluid medium under variable working conditions

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis. 

Glucosamine derivatives and pharmaceutical uses thereof

Provided herein are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) having the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Chimeric antigen receptors targeting BCMA and methods of use thereof

CD73 (also known as ecto-5'-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof. 

CD73 inhibitors and pharmaceutical uses thereof

The present invention discloses a reconfigurable wideband phase-switched screen (PSS) based on an artificial magnetic conductor (AMC). Gap capacitance between patches is controlled by changing the capacitance of varactors, so that periodic units have a plurality of continuous frequency points. A phase difference between two adjacent frequency bands is 143&#xb0;-217&#xb0;, so that the periodic structure absorbs incident electromagnetic waves in a wide frequency band, and the broadband PSS is implemented with a relative bandwidth of 45.2%. The AMC structure according to the present invention is simple in structure and easy to process, with a thickness less than one twentieth of the working wavelength, and greatly reduces size and costs.

Reconfigurable wideband phase-switched screen based on artificial magnetic conductor

Provided are a crystal form of an oxopicolinamide derivative and a preparation method therefor. In particular, provided are crystal forms A, B, C, D, E, and F of a compound as shown in formula (I) and a preparation method therefor. Crystal forms A, B, C, D, E, and F of the compound of formula (I) obtained in the present disclosure have good crystal stability and chemical stability, and can be better used in clinical treatment. 

Crystal form of oxopicolinamide derivative and preparation method therefor

The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Relating to an opioid receptor agonist (1S,4S)-4-ethoxy-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]deca-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine fumarate salt, a fumarate salt crystal form I thereof, and a preparation method and an application therefor. 

Opioid receptor (MOR) agonist salt, fumarate salt crystal form I thereof and preparation method thereof

The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Chimeric antigen receptors based on single domain antibodies and methods of use thereof

An illuminator is provided, comprising a support frame arranged symmetrically around an optical axis of an optical sensor. The illuminator includes at least one light bar connected to the support frame. At least one light source is connected to the support frame, wherein each of the at least one light source is configured to direct light towards one of the opposing ends of one of the at least one light bar. The illuminator further includes a peripheral cover configured to receive light emitted from the front face of each of the at least one light bar. The peripheral cover is further configured to emit dark field illumination at a low incident angle with respect to a plane perpendicular to the optical axis and to emit bright field illumination at a high incident angle with respect to the plane perpendicular to the optical axis.

Illuminator for a barcode scanner

Barcode reading devices for creating an easy-to-use experience are provided. In one implementation, a barcode reading apparatus comprises a housing having at least a scan body and an image sensor disposed within the housing. The image sensor is configured to read the barcode. The apparatus further includes a scanning frame and a viewing frame. The scanning frame is formed in a first bottom surface of the scan body and is configured to enable the image sensor to visually detect the barcode when the barcode is placed in a scanning zone at least partially below the scan body. The viewing frame is formed in a first top surface of the scan body and is configured to enable a user to view the barcode through both the viewing frame and scanning frame when the barcode is placed in the scanning zone.

Barcode reader with viewing frame

The present application discloses an exhaust gas after-treatment mixing device including a first plate, a second plate and a mixer. The mixer includes a first space, a second space and a third space located between the first space and the second space. Top portions of the first space and the second space are in communication with the third space. The mixer includes a first raised portion protruding into the third space and a second raised portion located below the first raised portion. A fourth space is formed between the first raised portion and the second raised portion. As a result, the distance and time of urea evaporation is increased and the mixing uniformity is improved. Besides, a package with the exhaust gas after-treatment mixing device is also provided.

Exhaust gas after-treatment mixing device and package therefor

Growing community of inventors

Suzhou, China

Lin Wang